Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603041 · ClinicalTrials.gov registry record · NA
Nutrition, Body Composition, and Sleep
A NA study, sponsored by University of Arkansas, Fayetteville.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT03603041: Completed NA study, sponsored by University of Arkansas, Fayetteville.
NCT03603041 is a NA study that has completed, run by University of Arkansas, Fayetteville. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03603041, a NA study, has completed, sponsored by University of Arkansas, Fayetteville.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of the research is to determine if protein and omega-3 fatty acid supplementation improve sleep, improve body composition, and improve markers of metabolic health in postmenopausal women.
Primary Outcome
Pittsburgh Sleep Quality Index (PSQI) will assess sleep quality and disturbance. This is a elf-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. Each item is weighted
Interventions
- DIETARY_SUPPLEMENT Omega-3 fatty acids
- DIETARY_SUPPLEMENT Whey protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
What the finished NCT03603041 record still lists
NCT03603041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Omega-3 fatty acids is the first listed.
NCT03603041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03603041 about?
NCT03603041 is a clinical study titled "Nutrition, Body Composition, and Sleep". The purpose of the research is to determine if protein and omega-3 fatty acid supplementation improve sleep, improve body composition, and improve markers of metabolic health in postmenopausal women.
What is the current status of trial NCT03603041?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2018-07-16. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03603041?
The interventions under investigation include: Omega-3 fatty acids (DIETARY_SUPPLEMENT), Whey protein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03603041?
This trial is sponsored by University of Arkansas, Fayetteville, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03603041's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI